A 3 Weeks Open Label Study to Evaluate the Efficacy in Agitation and Safety of Quetiapine Fumarate XR in Treatment of Patients With Acute Schizophrenia.
Phase of Trial: Phase IV
Latest Information Update: 21 Nov 2015
At a glance
- Drugs Quetiapine (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 28 Jul 2010 Additional lead investigator (Badiah Yahya, MD) identified as reported by ClinicalTrials.gov.
- 27 Jul 2010 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
- 27 Jul 2010 Actual initiation date (April 2010) added as reported by ClinicalTrials.gov.